Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Kovacs has received pharmaceutical company grant monies from Actelion Austria GmbH, as well as travel accommodations and speaking honoraria from multiple pharmaceutical companies, including Actelion, GlaxoSmithKline, Astra Zeneca, and Bayer-Schering Pharma. Dr Maier has received pharmaceutical company grant monies and participated in speaking activities for Actelion. Dr Brodmann has received pharmaceutical company grant monies from Sanofi-Aventis and participated in speaking activities from Sanofi-Aventis Austria, Bayer Austria GmbH, Actelion, and Boehringer Ingelheim. Dr Gruenig has been on advisory boards for Actelion, Lilly, GlaxoSmithKline, and Pfizer. Dr Gruenig also has done research for Bayer HealthCare, Actelion, Pfizer, Gilead Sciences, Inc, Mondogen Ag, Ergonex Pharma GmbH, and GlaxoSmithKline, and participated in speaking activities for Bayer HealthCare, Actelion, Pfizer, Lilly, Encysive Pharmaceuticals, and GlaxoSmithKline. Dr Olschewski received university, European Union, and pharmaceutical industry grant monies and royalties from Actelion, Pfizer, Bayer-Schering Pharma, and GlaxoSmithKline. Dr Olschewski also is a consultant to Unither, Novartis, and Bayer-Schering Pharma, and had speaking activities for Actelion, Bayer-Schering Pharma, GlaxoSmithKline, Pfizer, and Unither. Drs Aberer, Scheidl, Hesse, Troester, Salmhofer, Stauber, Fuerst, Thonhofer, and Ofner-Kopeinig have reported that no potential conflicts exist with any companies/organizations whose products or services may be discussed in this article.